Logo
x

Search

Subscribe Now

rheumatoid arthritis

Fresenius Kabi Reports Results of MSB11456 (biosimilar- tocilizumab) in Two Clinical Trials for the Treatment of Rheumatoid Arthritis

Fresenius Kabi Reports Results of MSB11456 (biosimilar- tocilizumab) in Two Clinical Trials for the Treatment of Rheumatoid Arthri...

  • September 7, 2021
Celltrion Launches Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis in Canada

Celltrion Launches Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis in Canada

  • June 7, 2021
Celltrion Presents One Year Results of Yuflyma (biosimilar- adalimumab) in P-III CT-P17 3.1 Trial for Rheumatoid Arthritis at EULAR 2021

Celltrion Presents One Year Results of Yuflyma (biosimilar- adalimumab) in P-III CT-P17 3.1 Trial for Rheumatoid Arthritis at EULA...

  • June 3, 2021
Biogen and Bio-Thera Report Results of BAT1806 (biosimilar- tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthritis

Biogen and Bio-Thera Report Results of BAT1806 (biosimilar- tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthriti...

  • June 3, 2021
AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheumatoid Arthritis at EULAR 2021

AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheu...

  • June 2, 2021
Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar- tocilizumab) to Treat Moderate to Severe Rheumatoid Arthritis

Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar- tocilizumab) to Treat Moderate to S...

  • April 9, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.